FIELD: chemistry.
SUBSTANCE: invention refers to the improved method of the preparation of calcium salt (E)-7-[4-(4-phtorphenyl)-6-isopropyl-2-[methyl(mesyl) amino]pyrimidine-5] (3R,5S)- 3.5-dihydroxyhepten-6 acid (rosuvastin),adding chloride solution into water soluble salt solution (E)-7-[4-(4-phtorphenyl)-6-isopropyl-2-[methyl(mesyl) amino]pyrimidine-5] (3R,5S)- 3.5-dihydroxyhepten-6 acid at 30-45°C temperature. Preferable time of addition is 5-60 minutes. After adding calcium chloride, the mixture is blended usually during ageing time at least 10 minutes at 30-45°C, filtered, if it is necessary the mixture is flushed out, the prepared product is dried. The temperature of the mixture during ageing should be equal to the temperature of addition. Moreover the temperature and time of addition, duration of addition are regulated in such way that to get the product with specific surface less or equal 1m/g (if the Fisher's method is used), preferably, to get the product with specific surface less or equal 0.5 m2/g (if the Fisher's method is used). The end product has the paste concentration of more than about 45% weight ratio. The paste concentration of the product is at least 50% of weight ratio after maximum 15 minutes of filtration by laboratory scale. Preferably, to prepare the product with the paste concentration more than about 70% weight ratio. Alcali salt can be used as water soluble salt solution (E)-7-[4-(4-phtorphenyl)-6-isopropyl-2-[methyl(mesyl) amino]pyrimidine-5] (3R,5S)- 3.5-dihydroxyhepten-6 acid, for example sodium salt or ammonium salt, methylamine salt or tris (tris(hydroxymethyl)aminomethane) salt.
EFFECT: salt is prepared by means of treating of acid or its salt with the corresponded base.
27 cl, 1 tbl, 4 ex
Title |
Year |
Author |
Number |
METHOD OF PRODUCING CALCIUM SALT (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROYL-2-[METHYL(METHYSUFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)3,5-DIHYDROXYHEPT-6-ENOIC ACID (ROSUVASTATIN CALCIUM SALT) |
2004 |
- Krabb Dzheffri Norman
- Khorberi Dzhon
- Tejlor Najdzhel Filip
|
RU2361864C2 |
CRYSTALLINE FORM OF CALCIUM SALT OF BIS-[(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]-PYRIMIDIN-5-YL](3R, 5S)-3, 5-DIHYDROXYHEPT-6-ENOIC ACID |
2004 |
- But Rebekka Dzhejn
- Sittern Piter Ehntoni
- Krabb Dzheffri Norman
- Khorberi Dzhon
- Dzhouns Dejvid Uin Kalvert
|
RU2363697C2 |
7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN -5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID CRYSTALLINE SALTS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION |
2001 |
- Tehjlor Najdzhel Filip
- Okada Tetsuo
|
RU2265599C2 |
METHOD OF PRODUCING ROSUVASTATIN CALCIUM SALT (E) -7-[4-(4-FLUOROPHEHYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATE PRODUCTS THEREOF |
2004 |
- Okada Tetsuo
- Khorberi Dzhon
- Laffan Dejvid Dermot Patrik
|
RU2372349C2 |
PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITOR OF HMG-REDUCTASE |
2000 |
- Krikmor Dzhozef Richard
- Uigginz Norman Al'Fred
|
RU2206324C1 |
PHARMACEUTICAL COMPOSITION COMPRISING INHIBITOR OF HMG-COA- REDUCTASE |
2000 |
- Krikmor Dzhozef Richard
- Vidzhins Norman Alfred
|
RU2264210C2 |
TERTIARY BUTYL-(E)-(6-{2-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL}-(4R,6S)-2,2-DIMETHYL[1,3]DIOXANE-4-YL]ACETATE AND METHOD FOR ITS PREPARING, DIPHENYL-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YLMETHYL]PHOSPHINE OXIDE, METHODS FOR PREPARING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND ITS DERIVATIVES |
2000 |
- Koike Kharuo
- Kabaki Mikio
- Tehjlor Najdzhel Filip
- Dioratsio Lui Dzhozef
|
RU2243969C2 |
CRYSTALLINE HYDRATED FORM OF BIS-[(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID] CALCIUM SALT, METHOD FOR ITS PREPARING, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARING AND METHOD FOR TREATMENT |
1999 |
|
RU2236404C2 |
APPLICATION OF 3-HYDROXY-3-METHTYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN PRODUCING MEDICINAL AGENT FOR TREATMENT OF DIABETIC NEUROPATHY |
2000 |
- Kehmeron Norman Judzhin
- Kotter Mehri Ehnn
|
RU2239456C2 |
APPLICATION OF ROSUVASTATIN (ZD-4522) IN TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
2001 |
- Rehjza Ali
- Khatchinson Khauard Dzherard
|
RU2294744C2 |